Neuberger Berman Group
CTKB icon

Neuberger Berman Group’s Cytek Biosciences CTKB Stock Holding History

Neuberger Berman Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,229
Closed -$49.1K – 2349
2026
Q1 		$49.1K Sell
11,229
-1,175
-9% -$5.55K ﹤0.01% 2116
2025
Q4 		$62.6K Buy
+12,404
New +$57.6K ﹤0.01% 2040
2025
Q2 		– Sell
-13,972
Closed -$56K – 2068
2025
Q1 		$56K Buy
+13,972
New +$72.4K ﹤0.01% 1908

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Neuberger Berman Group's CTKB Position: Q2 2026 in Review

Neuberger Berman Group sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 11,229 shares — an estimated $49.1K sold.

Neuberger Berman Group first reported a position in CTKB in Q1 2025 and held it in 3 quarters. The position peaked at $62.6K in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Neuberger Berman Group reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 11,229 Cytek Biosciences shares in Q2 2026, an estimated $49.1K.
  • Neuberger Berman Group first reported a position in Cytek Biosciences in Q1 2025 and held it in 3 quarters.
  • Neuberger Berman Group's Cytek Biosciences position peaked at $62.6K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.